iTind

iTind is a promising Israeli medical device company dedicated to improving men's healthcare and quality of life through effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The company's flagship product, iTind, has received the EU CE Mark and approvals for sale in various countries, including the European Union, UK, Israel, Australia, Brazil, and is FDA cleared for use in the USA. The iTind treatment offers a clinically-proven solution for relieving lower urinary tract symptoms caused by an enlarged prostate, or BPH. Unlike traditional methods, iTind reshapes the anatomy of the prostatic urethra without burning or cutting out tissue, and without leaving behind a permanent implant. The outpatient procedure has minimal downtime and is designed to preserve sexual function, making it a promising alternative to prescription medication or major surgery. This innovative approach presents several advantages, including rapid symptom relief in the majority of patients, minimal downtime, preservation of sexual function, and durable results demonstrated in clinical studies out to 3 years. With its focus on addressing the needs of active patients, iTind offers a promising solution in the treatment of BPH that aligns with the growing trend towards minimally-invasive and effective medical interventions.